ArticleMolecular medicine reports2017
Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The histone demethylase PHF8 regulates TGFβ signaling and promotes melanoma metastasis.Science advances · 2022Pooled it
- Epigenetic regulation of serine biosynthesis by PHF8 during neurogenesis.EMBO reports · 2026Article
- MicroRNAs as Biomarkers for the Diagnosis and Prognosis of Different Diseases and Cancer.Experientia supplementum (2012) · 2026Review
- HER3 promotes triple-negative breast cancer progression by upregulating PHF8 via miR-34b-5p-dependent mechanism.Cell death & disease · 2025Article
- Demystifying the Role of Histone Demethylases in Colorectal Cancer: Mechanisms and Therapeutic Opportunities.Current issues in molecular biology · 2025Review
- hnRNPA2B1 drives colorectal cancer progression via the circCDYL/EIF4A3/PHF8 axis.The Kaohsiung journal of medical sciences · 2025Article
- Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers.Journal of experimental & clinical cancer research : CR · 2025Article
- PHF8/KDM7B: A Versatile Histone Demethylase and Epigenetic Modifier in Nervous System Disease and Cancers.Epigenomes · 2024Review
- Epigenetic instability caused by absence of CIZ1 drives transformation during quiescence cycles.BMC biology · 2023Article
- Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons.Nature communications · 2023Article
- Expression Patterns of PAK4 and PHF8 Are Associated with the Survival of Gallbladder Carcinoma Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Variants inHGG advances · 2022Article
- MicroRNA-383: A tumor suppressor miRNA in human cancer.Frontiers in cell and developmental biology · 2022Review
- Circular RNA hsa_circ_0000751 serves as a microRNA-488 sponge to suppress gastric cancer progression via ubiquinol-cytochrome c reductase core protein 2 regulation.Bioengineered · 2021Article
- Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3.Journal of clinical laboratory analysis · 2021Article
- An in silico approach to identify and prioritize miRNAs target sites polymorphisms in colorectal cancer and obesity.Cancer medicine · 2020Article
- MicroRNA-383 inhibits proliferation, migration, and invasion in hepatocellular carcinoma cells by targeting PHF8.Molecular genetics & genomic medicine · 2020Article
- miR‑488 negatively regulates osteogenic differentiation of bone marrow mesenchymal stem cells induced by psoralen by targeting Runx2.Molecular medicine reports · 2019Article
- MicroRNA-488 inhibits endometrial glandular epithelial cell proliferation, migration, and invasion in endometriosis mice via Wnt by inhibiting FZD7.Journal of cellular and molecular medicine · 2019Article
- MicroRNA-488 inhibits proliferation, invasion and EMT in osteosarcoma cell lines by targeting aquaporin 3.International journal of oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant homeo domain finger protein 8 (PHF8), as an oncogene, has been highlighted in cancer development and progression. However, its clinical significance and underlying molecular mechanisms in colorectal cancer (CRC) remain to be fully elucidated. In the present study, the role of PHF8 in the progression of CRC was investigated. The mRNA and protein levels of PHF8 in tissues from patients with CRC and cell lines were detected using the reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. Cell viability was analyzed using an MTT assay. The targeted genes were predicted using a bioinformatics algorithm and confirmed by a dual luciferase reporter assay. Cell migration was evaluated using a Transwell assay. The results demonstrated that the expression of PHF8 was significantly increased in tumor tissues from patients with CRC and was correlated with tumor‑node‑metastasis stage. In addition, it was found that overexpressed PHF8 was a predictor of poor overall survival rates in patients with CRC. PHF8 loss‑of‑function significantly inhibited proliferation and migration, and promoted apoptosis of CRC cells. In addition, bioinformatics methods demonstrated that PHF8 was a putative target of microRNA (miR)‑488, and miR‑488 was able to inhibit the expression of PHF8 in CRC cells. miR‑488 loss‑of‑function showed increased proliferation and migration, and these effects were reversed by sh‑PHF8 transfection in CRC cells. In vitro and in vivo experiments revealed that PHF8 accelerated cancer cell growth and migration, confirming the oncogenic role of PHF8 in human CRC. In conclusion, PHF8 and miR‑488 may serve as CRC biomarkers for the prediction of clinical outcome and provide a target for the diagnosis and therapy of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.